Novavax Inc
Company Profile
Business description
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.
Contact
700 Quince Orchard Road
GaithersburgMD20878
USAT: +1 240 268-2000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
1,992
Stocks News & Analysis
stocks
Ask the analyst: Is the market underestimating Bapcor?
stocks
Is our ASX best idea still attractive after shares surge?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,751.60 | 4.00 | 0.05% |
| CAC 40 | 8,023.68 | 17.46 | 0.22% |
| DAX 40 | 21,982.10 | 70.36 | 0.32% |
| Dow JONES (US) | 44,470.41 | 167.01 | 0.38% |
| FTSE 100 | 8,764.42 | 3.38 | -0.04% |
| HKSE | 21,294.86 | 227.12 | -1.06% |
| NASDAQ | 19,714.27 | 190.87 | 0.98% |
| Nikkei 225 | 38,801.17 | 14.15 | 0.04% |
| NZX 50 Index | 12,917.45 | 41.10 | 0.32% |
| S&P 500 | 6,066.44 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,484.00 | 1.20 | 0.01% |
| SSE Composite Index | 3,318.06 | 4.11 | -0.12% |